Ivan Poullaos

Helped achieve significant trial, appellate, and summary judgment victories for a major cell culture device manufacturer accused of trade secret misappropriation, breach of contract, and patent infringement. The court found for the client on all issues after a month-long trial, and the Federal Circuit affirmed the judgment. The court also dismissed and entered summary judgment in the client’s favor on all asserted patents.

Achieved a notable trial win for a pharmaceutical company by convincing the court to invalidate the patent covering the active ingredient molecule in the Hepatitis B treatment, Baraclude® (entecavir). The decision was especially important because, for the first time, it invalidated as “obvious” a patent on a new chemical compound. The case received extensive press coverage, including articles in Forbes, Bloomberg, Law360, Inside Counsel, and countless IP, FDA, and patent law-related blogs. Ivan also represented this client in the appellate stage of the case, where the district court’s ruling was affirmed.

Ivan’s other noteworthy life sciences patent cases have included:

• Representation of a large brand pharmaceutical company in its defense of a groundbreaking gene therapy against allegations of patent infringement;
• Representation of a major brand pharmaceutical company regarding the COVID-19 vaccine and its delivery mechanism; 
• The anticancer treatments Clolar® (clofarabine), Faslodex® (fulvestrant), Temodar® (temozolomide), and Gilotrif® (afatinib);
• The opioid dependence treatment products Zubsolv®, Suboxone® tablets, and Subutex® tablets (buprenorphine and buprenorphine/naloxone);
• The pain relief products Lidoderm® (lidocaine patch), Exalgo® (hydromorphone HCl), and Abstral® (fentanyl sublingual tablets);
• The IBS (peptide) drug Linzess® (linaclotide);
• The antibiotics Omnicef® (cefdinir), and Dificid® (fidaxomicin);
• The nasal steroid drug Veramyst® (fluticasone furoate);
• The dementia treatment Exelon® (rivastigmine);
• The prostate treatment Avodart® (dutasteride);
• The estrogen modulator Evista® (raloxifene);
• The low testosterone treatments Fortesta® (testosterone gel) and Testim® (testosterone gel); and
• The diabetes and weight loss drugs Tradjenta® (linagliptin), Jentadueto® (linagliptin/metformin), and Qsymia® (phentermine/topiramate).

Ivan’s experience also includes a broad range of commercial, mechanical, and high-tech patent cases. For example, Ivan has represented:

• A worldwide leader in IT and networking in matters involving virtual private network (VPN) tunneling;
• Two leading high-tech companies in cases involving video processing technology and tablet computers;
• A financial technology firm in a patent infringement case involving software for electronic futures trading;
• A telecommunications firm in patent cases involving mobile telecommunications data networks and voice-over-IP systems;
• One of the world's leading technology companies in a suit relating to the development of its first smartphone;
• A defense firm in a patent case involving a “rolling code” security software algorithm;
• A railcar manufacturer in a patent case concerning gondola rail car designs;
• An agribusiness company in a mechanical patent case involving an enclosed belt conveyor; and
• A global automotive parts company in counseling concerning patents on brake rotors and brake pads.